Oncolytic viruses and histone deacetylase inhibitors-A multi-pronged strategy to target tumor cells

Cytokine and Growth Factor Reviews

Volumn 21, Issue 2-3, 2010, Pages 153-159

  Nguyen, Thi Lien Anh ^a   Wilson, Marnie Goodwin ^b   Hiscott, John ^a,b,c  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Combination therapy; Histone deacetylase inhibitors; Innate immune response; Interferons; Oncolytic virus

Indexed keywords

4 PHENYLBUTYRIC ACID; ALPHA INTERFERON; BELINOSTAT; BUTYRIC ACID; CARBOPLATIN; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; INTERFERON REGULATORY FACTOR 3; IRINOTECAN; JX 594; JX 929; N (2 AMINOPHENYL) 4 (3 PYRIDINYLMETHOXYCARBONYLAMINOMETHYL)BENZAMIDE; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; OBP 301; ONCOLYTIC ADENOVIRUS; ONCOLYTIC HERPES VIRUS; ONCOLYTIC MEASLES VIRUS; ONCOLYTIC REOVIRUS VIRUS; ONCOLYTIC VESICULAR STOMATITIS VIRUS; ONCOLYTIC VIRUS; OXAMFLATIN; PACLITAXEL; PANOBINOSTAT; PV 701; ROMIDEPSIN; STAT1 PROTEIN; TELOMELYSIN; TRICHOSTATIN A; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALPROIC ACID; VORINOSTAT; ANTINEOPLASTIC AGENT;

ADENOVIRUS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER GENE THERAPY; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CUTANEOUS T CELL LYMPHOMA; DRUG EFFICACY; DRUG TOLERABILITY; EPIGENETICS; GENE EXPRESSION REGULATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HERPES SIMPLEX VIRUS; HUMAN; INNATE IMMUNITY; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; MELANOMA; NONHUMAN; ONCOLYTIC VIROTHERAPY; OVARY CANCER; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PERIPHERAL T CELL LYMPHOMA; PERITONEUM CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR CELL DESTRUCTION; TUMOR REGRESSION; VESICULAR STOMATITIS VIRUS; VIRUS REPLICATION; ADENOVIRIDAE; ANIMAL; CLINICAL TRIAL (TOPIC); GENETIC EPIGENESIS; GENETICS; METABOLISM; MULTIMODALITY CANCER THERAPY; NEOPLASMS; PROCEDURES;

ADENOVIRIDAE; ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; EPIGENESIS, GENETIC; HISTONE DEACETYLASE INHIBITORS; HUMANS; IMMUNITY, INNATE; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; VIRUS REPLICATION;

EID: 77953544825     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2010.03.002     Document Type: Review

References (60)

1. Cattaneo R., Miest T., Shashkova E.V., Barry M.A. Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 2008, 6(7):529-540.
2. Sinkovics J.G., Horvath J.C. Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 2008, 56(Suppl. 1):3s-59s.
3. Prestwich R.J., Errington F., Diaz R.M., Pandha H.S., Harrington K.J., Melcher A.A., et al. The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon. Hum Gene Ther 2009, 20(10):1119-1132.
4. Tysome J.R., Lemoine N.R., Wang Y. Combination of anti-angiogenic therapy and virotherapy: arming oncolytic viruses with anti-angiogenic genes. Curr Opin Mol Ther 2009, 11(6):664-669.
5. Kaur B., Cripe T.P., Chiocca E.A. " Buy one get one free": armed viruses for the treatment of cancer cells and their microenvironment. Curr Gene Ther 2009, 9(5):341-355.
6. Thorne S.H., Hermiston T., Kirn D. Oncolytic virotherapy: approaches to tumor targeting and enhancing antitumor effects. Semin Oncol 2005, 32(6):537-548.
7. Dorer D.E., Nettelbeck D.M. Targeting cancer by transcriptional control in cancer gene therapy and viral oncolysis. Adv Drug Deliv Rev 2009, 61(7-8):554-571.
8. Li Q.X., Yu D.H., Liu G., Ke N., McKelvy J., Wong-Staal F. Selective anticancer strategies via intervention of the death pathways relevant to cell transformation. Cell Death Differ 2008, 15(8):1197-1210.
9. Liu T.C., Hwang T.H., Bell J.C., Kirn D.H. Development of targeted oncolytic virotherapeutics through translational research. Expert Opin Biol Ther 2008, 8(9):1381-1391.
10. Liu T.C., Galanis E., Kirn D. Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress. Nat Clin Pract Oncol 2007, 4(2):101-117.
11. Msaouel P., Dispenzieri A., Galanis E. Clinical testing of engineered oncolytic measles virus strains in the treatment of cancer: an overview. Curr Opin Mol Ther 2009, 11(1):43-53.
12. Harrington K.J., Melcher A., Vassaux G., Pandha H.S., Vile R.G. Exploiting synergies between radiation and oncolytic viruses. Curr Opin Mol Ther 2008, 10(4):362-370.
13. Kumar S., Gao L., Yeagy B., Reid T. Virus combinations and chemotherapy for the treatment of human cancers. Curr Opin Mol Ther 2008, 10(4):371-379.
14. Nguyen T.L., Tumilasci V.F., Singhroy D., Arguello M., Hiscott J. The emergence of combinatorial strategies in the development of RNA oncolytic virus therapies. Cell Microbiol 2009, 11(6):889-897.
15. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., Andrea M.J. Intelligent design: combination therapy with oncolytic viruses. Mol Ther 2010, 18(2):251-263.
16. Balasubramanian S., Verner E., Buggy J.J. Isoform-specific histone deacetylase inhibitors: the next step?. Cancer Lett 2009, 280(2):211-221.
17. Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett 2009, 280(2):168-176.
18. Bolden J.E., Peart M.J., Johnstone R.W. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006, 5(9):769-784.
19. Marchion D., Munster P. Development of histone deacetylase inhibitors for cancer treatment. Expert Rev Anticancer Ther 2007, 7(4):583-598.
20. Glaser K.B. HDAC inhibitors: clinical update and mechanism-based potential. Biochem Pharmacol 2007, 74(5):659-671.
21. Rosato R.R., Grant S. Histone deacetylase inhibitors: insights into mechanisms of lethality. Expert Opin Ther Targets 2005, 9(4):809-824.
22. Xu W.S., Parmigiani R.B., Marks P.A. Histone deacetylase inhibitors: molecular mechanisms of action. Oncogene 2007, 26(37):5541-5552.
23. Buchwald M., Kramer O.H., Heinzel T. HDACi-targets beyond chromatin. Cancer Lett 2009, 280(2):160-167.
24. Kristensen L.S., Nielsen H.M., Hansen L.L. Epigenetics and cancer treatment. Eur J Pharmacol 2009, 625(1-3):131-142.
25. Lane A.A., Chabner B.A. Histone deacetylase inhibitors in cancer therapy. J Clin Oncol 2009, 27(32):5459-5468.
26. Prince H.M., Bishton M.J., Harrison S.J. Clinical studies of histone deacetylase inhibitors. Clin Cancer Res 2009, 15(12):3958-3969.
27. Dokmanovic M., Clarke C., Marks P.A. Histone deacetylase inhibitors: overview and perspectives. Mol Cancer Res 2007, 5(10):981-989.
28. Duvic M., Vu J. Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma. Expert Opin Investig Drugs 2007, 16(7):1111-1120.
29. Stojdl D.F., Lichty B.D., tenOever B.R., Paterson J.M., Power A.T., Knowles S., et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4(4):263-275.
30. Nusinzon I., Horvath C.M. Positive and negative regulation of the innate antiviral response and beta interferon gene expression by deacetylation. Mol Cell Biol 2006, 26(8):3106-3113.
31. Tang X., Gao J.S., Guan Y.J., McLane K.E., Yuan Z.L., Ramratnam B., et al. Acetylation-dependent signal transduction for type I interferon receptor. Cell 2007, 131(1):93-105.
32. Genin P., Morin P., Civas A. Impairment of interferon-induced IRF-7 gene expression due to inhibition of ISGF3 formation by trichostatin A. J Virol 2003, 77(12):7113-7119.
33. Chang H.M., Paulson M., Holko M., Rice C.M., Williams B.R., Marie I., et al. Induction of interferon-stimulated gene expression and antiviral responses require protein deacetylase activity. Proc Natl Acad Sci USA 2004, 101(26):9578-9583.
34. Nguyen T.L., Abdelbary H., Arguello M., Breitbach C., Leveille S., Diallo J.S., et al. Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis. Proc Natl Acad Sci USA 2008, 105(39):14981-14986.
35. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008, 13:2060-2064.
36. Mohr I. Neutralizing innate host defenses to control viral translation in HSV-1 infected cells. Int Rev Immunol 2004, 23(1-2):199-220.
37. Mohr I. To replicate or not to replicate: achieving selective oncolytic virus replication in cancer cells through translational control. Oncogene 2005, 24(52):7697-7709.
38. He B., Chou J., Brandimarti R., Mohr I., Gluzman Y., Roizman B. Suppression of the phenotype of gamma(1)34.5-herpes simplex virus 1: failure of activated RNA-dependent protein kinase to shut off protein synthesis is associated with a deletion in the domain of the alpha47 gene. J Virol 1997, 71(8):6049-6054.
39. Post D.E., Fulci G., Chiocca E.A., Van Meir E.G. Replicative oncolytic herpes simplex viruses in combination cancer therapies. Curr Gene Ther 2004, 4(1):41-51.
40. Benencia F., Courreges M.C., Conejo-Garcia J.R., Buckanovich R.J., Zhang L., Carroll R.H., et al. Oncolytic HSV exerts direct antiangiogenic activity in ovarian carcinoma. Hum Gene Ther 2005, 16(6):765-778.
41. Cinatl J., Michaelis M., Driever P.H., Cinatl J., Hrabeta J., Suhan T., et al. Multimutated herpes simplex virus g207 is a potent inhibitor of angiogenesis. Neoplasia 2004, 6(6):725-735.
42. Otsuki A., Patel A., Kasai K., Suzuki M., Kurozumi K., Chiocca E.A., et al. Histone deacetylase inhibitors augment antitumor efficacy of herpes-based oncolytic viruses. Mol Ther 2008, 16(9):1546-1555.
43. Liu T.C., Castelo-Branco P., Rabkin S.D., Martuza R.L. Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther 2008, 16(6):1041-1047.
44. Katsura T., Iwai S., Ota Y., Shimizu H., Ikuta K., Yura Y. The effects of trichostatin A on the oncolytic ability of herpes simplex virus for oral squamous cell carcinoma cells. Cancer Gene Ther 2009, 16(3):237-245.
45. Cody J.J., Douglas J.T. Armed replicating adenoviruses for cancer virotherapy. Cancer Gene Ther 2009, 16(6):473-488.
46. Rein D.T., Breidenbach M., Curiel D.T. Current developments in adenovirus-based cancer gene therapy. Future Oncol 2006, 2(1):137-143.
47. Kitazono M., Goldsmith M.E., Aikou T., Bates S., Fojo T. Enhanced adenovirus transgene expression in malignant cells treated with the histone deacetylase inhibitor FR901228. Cancer Res 2001, 61(17):6328-6330.
48. Kitazono M., Rao V.K., Robey R., Aikou T., Bates S., Fojo T., et al. Histone deacetylase inhibitor FR901228 enhances adenovirus infection of hematopoietic cells. Blood 2002, 99(6):2248-2251.
49. Sachs M.D., Ramamurthy M., Poel H., Wickham T.J., Lamfers M., Gerritsen W., et al. Histone deacetylase inhibitors upregulate expression of the coxsackie adenovirus receptor (CAR) preferentially in bladder cancer cells. Cancer Gene Ther 2004, 11(7):477-486.
50. Fan S., Maguire C.A., Ramirez S.H., Bradel-Tretheway B., Sapinoro R., Sui Z., et al. Valproic acid enhances gene expression from viral gene transfer vectors. J Virol Methods 2005, 125(1):23-33.
51. Goldsmith M.E., Kitazono M., Fok P., Aikou T., Bates S., Fojo T. The histone deacetylase inhibitor FK228 preferentially enhances adenovirus transgene expression in malignant cells. Clin Cancer Res 2003, 9(14):5394-5401.
52. Goldsmith M.E., Aguila A., Steadman K., Martinez A., Steinberg S.M., Alley M.C., et al. The histone deacetylase inhibitor FK228 given prior to adenovirus infection can boost infection in melanoma xenograft model systems. Mol Cancer Ther 2007, 6(2):496-505.
53. Vanoosten R.L., Moore J.M., Ludwig A.T., Griffith T.S. Depsipeptide (FR901228) enhances the cytotoxic activity of TRAIL by redistributing TRAIL receptor to membrane lipid rafts. Mol Ther 2005, 11(4):542-552.
54. Vanoosten R.L., Earel J.K., Griffith T.S. Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors. Cancer Gene Ther 2006, 13(6):628-632.
55. Vanoosten R.L., Earel J.K., Griffith T.S. Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 2007, 12(3):561-571.
56. Watanabe T., Hioki M., Fujiwara T., Nishizaki M., Kagawa S., Taki M., et al. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells. Exp Cell Res 2006, 312(3):256-265.
57. Bieler A., Mantwill K., Dravits T., Bernshausen A., Glockzin G., Kohler-Vargas N., et al. Novel three-pronged strategy to enhance cancer cell killing in glioblastoma cell lines: histone deacetylase inhibitor, chemotherapy, and oncolytic adenovirus dl520. Hum Gene Ther 2006, 17(1):55-70.
58. Wakimoto H., Fulci G., Tyminski E., Chiocca E.A. Altered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysis. Gene Ther 2004, 11(2):214-223.
59. Alain T., Lun X., Martineau Y., Sean P., Pulendran B., Petroulakis E., et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci USA 2010, 107(4):1576-1581.
60. Breitbach C.J., Paterson J.M., Lemay C.G., Falls T.J., McGuire A., Parato K.A., et al. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow. Mol Ther 2007, 15(9):1686-1693.